Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
International Journal of Oncology|May 13, 2004
ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cellsHisashi Suyama, Tadashi Igishi, Hiroyuki Sano, et al.
Chronobiology International|August 4, 2005
Dexamethasone influences human clock gene expression in bronchial epithelium and peripheral blood mononuclear cells in vitroNaoto Burioka, Miyako Takata, Yoko Okano, et al.
Therapeutic Drug Monitoring|September 28, 2007
Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 alleleHiroshi Takane, Masanori Miyata, Naoto Burioka, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 15, 2006
[A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin]Jun Kurai, Tadashi Igishi, Hisashi Suyama, et al.
Japanese Journal of Pharmacology|December 25, 2002
Daily expression of mRNAs for the mammalian Clock genes Per2 and clock in mouse suprachiasmatic nuclei and liver and human peripheral blood mononuclear cellsMiyako Takata, Naoto Burioka, Shigehiro Ohdo, et al.
Cancer Journal (Sudbury, Mass.)|April 15, 2006
The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patientsMasanori Miyata, Kazuhito Yasuda, Naoto Burioka, et al.
Oncology Reports|March 22, 2008
Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cellsKenichi Takeda, Hisashi Suyama, Tadashi Igishi, et al.
Life Sciences|July 21, 2009
Influence of intermittent hypoxia on the signal transduction pathways to inflammatory response and circadian clock regulationNaoto Burioka, Satoru Koyanagi, Yasushi Fukuoka, et al.
Clinical EEG and Neuroscience|September 1, 2005
Approximate entropy of the electroencephalogram in healthy awake subjects and absence epilepsy patientsNaoto Burioka, Germaine Cornélissen, Yoshihiro Maegaki, et al.
Oncology Reports|December 4, 2009
Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cellsHisashi Suyama, Tadashi Igishi, Yasuto Ueda, et al.
Pageof 4